Omnicell - OMCL Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OMCL shares.
View OMCL analyst ratings or view top-rated stocks.

8 Wall Street research analysts have issued 1-year target prices for Omnicell's shares. Their OMCL share price forecasts range from $120.00 to $205.00. On average, they predict the company's share price to reach $149.88 in the next twelve months. This suggests a possible upside of 75.5% from the stock's current price.
View analysts price targets for OMCL or view top-rated stocks among Wall Street analysts.

Omnicell's stock was trading at $180.44 at the start of the year. Since then, OMCL shares have decreased by 52.7% and is now trading at $85.42.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our OMCL earnings forecast.

Omnicell, Inc. (NASDAQ:OMCL) announced its quarterly earnings data on Thursday, August, 4th. The company reported $0.84 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.85 by $0.01. The business earned $331.39 million during the quarter, compared to analyst estimates of $339.45 million. Omnicell had a trailing twelve-month return on equity of 10.37% and a net margin of 4.82%. The business's revenue was up 21.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.71 earnings per share.

Omnicell updated its FY 2025 earnings guidance on Tuesday, September, 20th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.90 billion-$2.00 billion.

150 employees have rated Omnicell Chief Executive Officer Randall A. Lipps on Glassdoor.com. Randall A. Lipps has an approval rating of 68% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Adobe (ADBE), Micron Technology (MU), NVIDIA (NVDA), Applied Materials (AMAT), Alibaba Group (BABA) and Intel (INTC).

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Omnicell's stock is owned by many different institutional and retail investors. Top institutional shareholders include Conestoga Capital Advisors LLC (3.80%), Macquarie Group Ltd. (2.75%), Clearbridge Investments LLC (2.60%), Lazard Asset Management LLC (2.00%), Geneva Capital Management LLC (1.90%) and Price T Rowe Associates Inc. MD (1.11%). Insiders that own company stock include Christine Marie Mellon, Dan S Johnston, James T Judson, Joanne B Bauer, Joseph Brian Spears, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann.
View institutional ownership trends.

Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OMCL stock can currently be purchased for approximately $85.42.

Omnicell (NASDAQ:OMCL) has a market capitalization of $3.78 billion and generates $1.13 billion in revenue each year. The company earns $77.85 million in net income (profit) each year or $1.26 on an earnings per share basis.

The company employs 3,800 workers across the globe.

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The official website for the company is www.omnicell.com. The company can be reached via phone at (650) 251-6100, via email at ir@omnicell.com, or via fax at 847-596-3402.